バイアスがアスピリン/レイ症候群の関連性を説明しないことを確認する新しい疫学的な証拠
B W Forsyth1, R I Horwitz, D Acampora
1Department of Pediatrics, Yale University School of Medicine, New Haven, Conn 06510.
JAMA
|May 5, 1989
まとめ
この研究では,アスピリンとレイ症候群の関連性を調査し,潜在的なバイアスを考慮した後でも持続する強い関連性を発見しました. 研究はアスピリンの使用がレイ症候群のリスクを大幅に増加させることを確認しています.
科学分野:
- エピデミオロジー エピデミオロジー
- 小児医学は,小児科の医学である.
- 公衆衛生は公衆衛生である.
背景:
- アスピリンの使用とレイ症候群 (RS) の関連性は,公衆衛生上の懸念事項となっています.
- 以前の研究では,リンクが示唆されていたが,潜在的なバイアスに関する懸念は残っていた.
研究 の 目的:
- アスピリン・レイ症候群関連の妥当性を厳密に評価する.
- バイアスの5つの特定の源を調査し,制御する:時間優先度,感受性,リコール,診断,および報告バイアス.
主な方法:
- ケース・コントロール・スタディ・デザインが採用されました.
- 特定の方法には,疾患パターンの分類,症状の重症度に対する対照群のマッチング,リコールバイアスに対処するために"代替条件"の対照群を使用すること,診断バイアスのための医療記録のレビュー,およびバイアスの報告のための地域病院の監視が含まれています.
主要な成果:
- レイ症候群患者の88%は,疾患発症前にアスピリンを服用しており,対照群では17%しか服用していなかった.
- 強い関連性が見られた (マッチした確率比=35;95%CI,4.2〜288).
- 統計的分析は,観察された関連は,調査されたバイアスの源に起因することができないことを示した.
結論:
- 疫学調査は,アスピリンの使用とレイ症候群の間の因果関係を支持する強力な証拠を提供します.
- この研究の強固な方法論は,潜在的なバイアスを効果的に軽減し,結果の妥当性を強化しました.
- これらの結果は,特にウイルス性疾患の間,子供や青少年においてアスピリンを避けることの重要性を強調しています.
関連する概念動画
Blind Procedures
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
Regression Toward the Mean
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when researchers try to extrapolate results...
Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
